What this means
Researchers will track people over 60 with kidney disease who take these granules for a year. The study has not reported results, so it cannot yet show whether the granules help.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 61 and over · About 300 older adults with kidney disease
- Where
- 1 site
The science
- Registered title
- Niaoduqing Granules in Older Adults With Impaired Kidney Function
- Trial ID
- NCT07741292 ↗
- Phase
- PHASE 4
- Study type
- interventional
- Conditions
- Chronic Kidney Disease
- What is tested
- Intervention Name
- Sponsor
- Huashan Hospital
- Ages
- 61 Years to no maximum
- Dates
- First posted Aug 3, 2026 · updated Aug 3, 2026
Registry summary
This prospective real-world study will evaluate the clinical benefits of Niaoduqing Granules in older adults with impaired kidney function. Approximately 300 participants aged over 60 years with stage 3 to 5 chronic kidney disease who are not receiving dialysis will be enrolled at Huashan Hospital, Fudan University. The study will examine whether treatment with Niaoduqing Granules is associated with slower kidney function decline and improvements in nutrition, frailty, and other health outcomes.
Participants will receive 5 g of Niaoduqing Granules three times daily after meals for 12 months, while continuing their usual treatment for chronic diseases as directed by their physicians. Kidney function, laboratory results, nutritional status, frailty, cardiovascular and cerebrovascular events, and survival will be assessed during follow-up. Blood, urine, and stool samples will also be collected to study changes in gut microorganisms and blood metabolites that may help explain how Niaoduqing Granules affect health. Participants will be followed for up to 60 months.
Sites (1)
- Huashan Hospital, Fudan University, Shanghai, Shanghai Municipality, China